Pharma racks up multibillion-dollar marketing bill

Drug marketing spending is staggering when you think about it: companies shell out $5 billion on DTC ads and $19 billion on so-called "doctor education." Their return on investment here isn't too shabby either: of the $279 billion spent on prescription drugs in 2006, Americans chose brand names 80 percent of the time.

The numbers tell a story that sharpens up what's becoming an old argument. Drug companies say it's all about educating patients and keeping doctors up-to-date on the latest science and technology. Critics say common conditions fixed with cheaper drugs go undertreated, but those that require expensive brand-name meds--the meds that are most heavily advertised to patients and docs alike--get plenty of attention. These branded drugs also contribute to skyrocketing healthcare costs: even a few billion off the top of that brand-name-fueled $279 billion could help. Agreed?

- read the spending report from The Los Angeles Times

Related Articles:
AMA to study the impact of drug advertising. Report
Does the FDA do enough to regulate drug ads? Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.